source
- Parker Institute chief urges renewed focus on cancer immunotherapy after mixed results from Revolution Medicines' drugIra Mellman, who leads research at the Parker Institute for Cancer Immunotherapy, said on Sept. 16, 2026 that he felt disappointment and frustration as the industry celebrated Revolution Medicines'…
- Merck KGaA receives FDA approval for Abbisko-licensed joint tumor therapyMerck KGaA announced that the U.S. Food and Drug Administration has granted approval to a drug it licensed from Chinese biotech Abbisko. The approval covers treatment of rare non-cancerous tumors t…